Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oncology

Oncology Teruhiko MD Yoshida, Masaaki MD Terada, National Cancer Center Research Institute, Tokyo, Japan have since the discov¬ the Human Genome where years passed Beyond Project, of the cellular src and of the total is proto-oncogene ery completion sequencing expected Twenty 9 since the of the first elucidation of the functions and inter¬ tumor years cloning by 2005, RB. In future 1996 will actions of cancer will be the next suppressor gene, years, genes major be remembered as a of maturation and in¬ research in One of the most year oncology. target the of the of era works last is the iden¬ tegration, bridging discovery important published year the individual cancer and the elucidation tification of new for the APC gene protein. partners of its functions the of coworkers10 to clinical Rubinfeld and have extended the years applica¬ tion of on cancer of scheme and the APC in knowledge genes. Cloning firmly placed protein the continues new cancer at an acceler¬ the WINGLESS (mouse genes (Drosophila)fWNT ated with notable the iden¬ of transduction rate, WINGLESS) examples being homolog signal tification of2 tumor The evidence now that in suppressor gene candidates, pathway. suggests and FHIT. the of excess DPCh presence uncomplexed http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Oncology

Yoshida, Teruhiko; Terada, Masaaki
JAMA , Volume 277 (23) – Jun 18, 1997
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/oncology-HmmR2igJ0J
Publisher
American Medical Association
Copyright
Copyright © 1997 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1997.03540470062034
Publisher site
See Article on Publisher Site

Abstract

Teruhiko MD Yoshida, Masaaki MD Terada, National Cancer Center Research Institute, Tokyo, Japan have since the discov¬ the Human Genome where years passed Beyond Project, of the cellular src and of the total is proto-oncogene ery completion sequencing expected Twenty 9 since the of the first elucidation of the functions and inter¬ tumor years cloning by 2005, RB. In future 1996 will actions of cancer will be the next suppressor gene, years, genes major be remembered as a of maturation and in¬ research in One of the most year oncology. target the of the of era works last is the iden¬ tegration, bridging discovery important published year the individual cancer and the elucidation tification of new for the APC gene protein. partners of its functions the of coworkers10 to clinical Rubinfeld and have extended the years applica¬ tion of on cancer of scheme and the APC in knowledge genes. Cloning firmly placed protein the continues new cancer at an acceler¬ the WINGLESS (mouse genes (Drosophila)fWNT ated with notable the iden¬ of transduction rate, WINGLESS) examples being homolog signal tification of2 tumor The evidence now that in suppressor gene candidates, pathway. suggests and FHIT. the of excess DPCh presence uncomplexed

Journal

JAMA – American Medical Association

Published: Jun 18, 1997

There are no references for this article.